Vital Therapies Outlines Plans for New Phase 3 Trial of ELAD(R) in Alcohol-Induced Liver Decompensation
28 sept. 2015 07h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Workforce and Cost Reduction Plans to Conserve Capital for a Possible New Clinical Trial
03 sept. 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Additional Data From VTI-208 Presented at Rostock Conference
31 août 2015 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces That Topline Results of VTI-208 Fail to Achieve Primary or Secondary Endpoints of Improvement in Overall Survival Pre-Specified Exploratory Subset Analyses Suggest Efficacy Trends
21 août 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 21, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Second Quarter 2015 Financial Results and Provides Corporate Update
30 juil. 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Second Quarter 2015 Financial Results Conference Call With Webcast Scheduled for Thursday, July 30, 2015
27 juil. 2015 03h05 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 27, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will...
Vital Therapies Announces Appointment of Former Medivation Chief Commercial Officer Cheryl Cohen to Its Board of Directors
15 juil. 2015 16h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Poster Presentation at International Liver Transplantation Society Meeting Today in Chicago
09 juil. 2015 16h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, July 9, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced...
Vital Therapies Announces First Quarter 2015 Financial Results and Provides a Corporate Update
12 mai 2015 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Poster Presentations From the Annual Meeting of the European Association for the Study of the Liver and Upcoming First Quarter Financial Results Conference Call With Webcast
27 avr. 2015 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...